Kaan Boztug awarded the "Işil Berat Barlan Award for Primary Immunodeficiency Diseases"

Kaan Boztug awarded the "Işil Berat Barlan Award for Primary Immunodeficiency Diseases"

(Vienna, 03.09.2021) Congratulations! Assoc.-Prof. Kaan Boztug, MD, Scientific Director of the St. Anna Children's Cancer Research Institute and Director of the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, has been awarded the Işil Berat Barlan Award for his outstanding research in the field of primary immunodeficiencies, which will be…

Childhood Cancer Awareness Month 2021 - St. Anna CCRI under the sign of the gold ribbon

Childhood Cancer Awareness Month 2021 - St. Anna CCRI under the sign of the gold ribbon

(Vienna, 01.09.2021) With our research, we aim to strike childhood cancer at its roots. In Austria, about 200 children and 100 adolescents are diagnosed with cancer each year. Thanks to research and the resulting major advances in treatment, 85% of affected children and adolescents are cured. However, about 30 children…

“Our results can have a direct impact on a child’s life”

“Our results can have a direct impact on a child’s life”

(Vienna, 17.8.2021) Together with colleagues, Artem Kalinichenko (37) discovered a novel gene defect causing a life-threatening immune disorder. Profiled as a YoungStar by St. Anna Children’s Cancer Research Institute (St. Anna CCRI), the scientist explains how to form a good hypothesis and under which circumstances he acquires aha-experiences. Artem Kalinichenko,…

“1000 Ideas” to boost childhood cancer research: St. Anna CCRI earns two grants in competitive FWF program

“1000 Ideas” to boost childhood cancer research: St. Anna CCRI earns two grants in competitive FWF program

(Vienna, 29.06.2021) Two projects from St. Anna Children’s Cancer Research Institute (St. Anna CCRI) receive funding from the “1000 Ideas Programme” of the Austrian Science Fund (FWF). The aim of this program is to support daring and original research ideas that lie outside the current scientific understanding. In the second…

Nerve tumor in children: study identifies better tolerable chemotherapy without loss of efficacy

Nerve tumor in children: study identifies better tolerable chemotherapy without loss of efficacy

(Vienna, 21.06.2021) The initial chemotherapy of aggressive childhood nerve tumors, so-called high-risk neuroblastomas, is crucial for ultimate survival. It has now been shown that the chemotherapy regimen used by the European Neuroblastoma Study Group is equally efficacious but better tolerated than a highly effective regimen from the US. This was…